Antimicrobial treatment of non-cystic fibrosis bronchiectasis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Review of Anti-Infective Therapy

• Publication date

  2014-09-09

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1586/14787210.2014.952282PMID 25156239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exacerbations of Cystic Fibrosis

  2016cited by this paper
• Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

  2015cited by this paper
• Detection of biofilm in bronchoalveolar lavage from children with non‐cystic fibrosis bronchiectasis

  2015cited by this paper
• Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children

  2014cited by this paper
• Molecular tracing of the emergence, diversification, and transmission of S. aureus sequence type 8 in a New York community

  2014cited by this paper
• Does failed chronic wet cough response to antibiotics predict bronchiectasis?

  2014cited by this paper
• Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.

  2014cited by this paper
• Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials.

  2014cited by this paper
• Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

  2014cited by this paper
• Bronchiectasis: the arrival of better evidence.

  2014cited by this paper
• Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.

  2014influential reference
• Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

  2014cited by this paper
• Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.

  2014cited by this paper
• Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.

  2014cited by this paper
• Adenovirus Species C Is Associated With Chronic Suppurative Lung Diseases in Children

  2014cited by this paper
• The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: A case–control analysis

  2014cited by this paper
• Nontuberculous Mycobacterial Disease Mortality in the United States, 1999–2010: A Population-Based Comparative Study

  2014cited by this paper
• Chronic suppurative lung disease in a developing country: Impact on child and parent

  2014cited by this paper
• A novel microbiota stratification system predicts future exacerbations in bronchiectasis.

  2014cited by this paper
• Three clinically distinct chronic pediatric airway infections share a common core microbiota.

  2014cited by this paper
• The bronchiectasis severity index. An international derivation and validation study.

  2014cited by this paper
• Non-typeable Haemophilus influenzae, an under-recognised pathogen.

  2014cited by this paper
• Macrolide antibiotics and the risk of cardiac arrhythmias.

  2014cited by this paper
• Azithromycin: mechanisms of action and their relevance for clinical applications.

  2014cited by this paper
• Bronchiectasis: an update on current pharmacotherapy and future perspectives

  2014influential reference
• Nontuberculous mycobacterial pulmonary infections.

  2014cited by this paper
• The evidence base for non‐CF bronchiectasis is finally evolving

  2014cited by this paper
• Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency.

  2014cited by this paper
• Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

  2014cited by this paper
• Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review

  2014cited by this paper
• Indigenous children from three countries with non‐cystic fibrosis chronic suppurative lung disease/bronchiectasis

  2014cited by this paper
• Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial

  2014cited by this paper
• Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis.

  2014cited by this paper
• Treatment adherence and health outcomes in patients with bronchiectasis

  2014cited by this paper
• Monitoring cystic fibrosis lung disease by computed tomography. Radiation risk in perspective.

  2014cited by this paper
• Vaccines for Pseudomonas aeruginosa: a long and winding road

  2014cited by this paper
• Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations

  2014cited by this paper
• Inhaled antibiotics for lower airway infections.

  2014cited by this paper
• Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis.

  2014cited by this paper
• Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

  2014cited by this paper
• Non-cystic fibrosis bronchiectasis.

  2013cited by this paper
• Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

  2013cited by this paper
• Microbes in bronchiectasis: the forest or the trees?

  2013cited by this paper
• Human Rhinoviruses

  2013cited by this paper
• Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.

  2013influential reference
• Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition

  2013cited by this paper
• Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

  2013cited by this paper
• Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

  2013cited by this paper
• Meta-Analysis of the Adverse Effects of Long-Term Azithromycin Use in Patients with Chronic Lung Diseases

  2013cited by this paper
• Use of azithromycin and death from cardiovascular causes.

  2013cited by this paper
• Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

  2013cited by this paper
• Effectiveness of Hospital-Wide Methicillin-Resistant Staphylococcus aureus (MRSA) Infection Control Policies Differs by Ward Specialty

  2013cited by this paper
• Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment?

  2013cited by this paper
• Factors That Impact Pseudomonas aeruginosa Biofilm Structure and Function

  2013cited by this paper
• Risks associated with the therapeutic use of fluoroquinolones

  2013cited by this paper
• Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis.

  2013cited by this paper
• Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

  2013cited by this paper
• Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

  2013cited by this paper
• Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB)

  2013cited by this paper
• Longitudinal Nasopharyngeal Carriage and Antibiotic Resistance of Respiratory Bacteria in Indigenous Australian and Alaska Native Children with Bronchiectasis

  2013cited by this paper
• Bronchoscopy contributes to the clinical management of indigenous children newly diagnosed with bronchiectasis

  2013cited by this paper
• Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases.

  2013influential reference
• Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis

  2013cited by this paper
• High rhinovirus burden in lower airways of children with cystic fibrosis.

  2013cited by this paper
• Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

  2013cited by this paper
• Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial

  2013cited by this paper
• Pseudomonas aeruginosa: new insights into pathogenesis and host defenses.

  2013cited by this paper
• Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial

  2013cited by this paper
• Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis.

  2013cited by this paper
• Microbes in Bronchiectasis: The Forest or the Trees?

  2013cited by this paper
• Impact of symptoms of anxiety and depression on COPD Assessment Test scores

  2013cited by this paper
• Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa.

  2013cited by this paper
• Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis

  2013cited by this paper
• Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

  2012cited by this paper
• Allergic bronchopulmonary aspergillosis.

  2012cited by this paper
• Azithromycin and the risk of cardiovascular death.

  2012cited by this paper
• Epidemiology of severe pediatric adenovirus lower respiratory tract infections in Manitoba, Canada, 1991-2005

  2012cited by this paper
• Evaluating success of therapy for bronchiectasis: what end points to use?

  2012cited by this paper
• Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial

  2012influential reference
• Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.

  2012influential reference
• Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

  2012cited by this paper
• Mycobacterium abscessus: a new antibiotic nightmare.

  2012cited by this paper
• Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score

  2012cited by this paper
• Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population.

  2012cited by this paper
• Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci.

  2012cited by this paper
• Lower airway microbiology and cellularity in children with newly diagnosed non‐CF bronchiectasis

  2012cited by this paper
• Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture.

  2012influential reference
• Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease.

  2012cited by this paper
• Defining pulmonary exacerbation in children with non‐cystic fibrosis bronchiectasis

  2012cited by this paper
• Pathogenesis of bronchiectasis.

  2012cited by this paper
• Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.

  2012cited by this paper
• Antimicrobial therapy for bronchiectasis.

  2012cited by this paper
• Antimicrobial Susceptibility Testing, Drug Resistance Mechanisms, and Therapy of Infections with Nontuberculous Mycobacteria

  2012cited by this paper
• Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

  2012cited by this paper
• Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis.

  2012cited by this paper
• The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.

  2012cited by this paper
• Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

  2012cited by this paper
• Bronchiectasis in patients with COPD: a distinct COPD phenotype?

  2011cited by this paper
• Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries.

  2011cited by this paper
• A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.

  2011cited by this paper

• The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions

  2023cites this paper
• Bronchiectasis in Childhood.

  2022cites this paper
• Bronchiectasis in Childhood (Including PBB)

  2021cites this paper
• The Relationship Between Long-term, Low-dose Macrolide Therapy and Acute Exacerbation in Idiopathic Bronchiectasis Classi ed by High- resolution Computed Tomography

  2020cites this paper
• International Journal of Current Microbiology and Applied Sciences

  2020cites this paper
• A review of non‐cystic fibrosis bronchiectasis in children with a focus on the role of long‐term treatment with macrolides

  2019cites this paper
• An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis

  2019cites this paper
• Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients

  2019cites this paper
• Contemporary management of bronchiectasis in children

  2019cites this paper
• A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart

  2018cites this paper
• Inhalation Techniques Used in Patients with Respiratory Failure Treated with Noninvasive Mechanical Ventilation

  2018cites this paper
• Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis––experiences from recent clinical trials

  2018cites this paper
• Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention

  2018cites this paper
• Bronchiectasis in children: diagnosis and treatment.

  2018cites this paper
• Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial

  2018cites this paper
• Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents

  2018cites this paper
• An Overview of Bronchiectasis in Children

  2018cites this paper
• Bronchiectasis and Chronic Suppurative Lung Disease

  2018cites this paper
• The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

  2017cites this paper
• Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults

  2017cites this paper
• Bronchiectasis in Children: Current Concepts in Immunology and Microbiology

  2017cites this paper
• The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis

  2017cites this paper
• An update on pediatric bronchiectasis

  2017cites this paper
• Development of Liposomal Ciprofloxacin to Treat Lung Infections

  2016cites this paper
• Pediatric bronchiectasis: No longer an orphan disease

  2016cites this paper
• Bacterial profile of blood stream infections and their antibiograms

  2015cites this paper
• Emerging drugs for bronchiectasis: an update

  2015cites this paper
• Efficiency and safety of surgical intervention to patients with Non-Cystic Fibrosis bronchiectasis: a meta-analysis

  2015cites this paper
• Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis

  2015cites this paper
• Emerging Opportunities for Inhaled Antibiotic Therapy

  2015cites this paper
• Recognition and management of children with protracted bacterial bronchitis.

  2015cites this paper
• Emerging drugs for bronchiectasis

  2012cites this paper